Biotechnology industry association BIO Deutschland celebrates its 20th anniversary
(Berlin – September 17, 2024) The biotechnology industry association BIO Deutschland e. V. is marking its 20th anniversary today. The association was founded exactly two decades ago in Frankfurt am Main with the aim of supporting innovative biotech start-ups. Today, BIO Deutschland represents the interests of more than 380 members of all sizes and at all levels of maturity, reflecting the full range of the biotechnology industry, from medical biotechnology with therapy and diagnostics development, contract research and production, to industrial biotechnology including nutrition and bioinformatics or AI and the associated industry clusters.
Oliver Schacht, Chairman of the Board of BIO Deutschland e. V., says: “We at BIO Deutschland can look back on 20 years of success. The founding of the association gave a voice to innovative start-ups and small and medium-sized biotech companies. Our industry has grown continuously over the last 20 years and continues to have great potential for growth. Biotechnology is also a future-oriented technology with high added value for Germany. Accordingly, the industry has developed in a diverse number of ways. Some start-ups have become hidden champions or world-renowned companies. New start-ups with innovative ideas are added every year. As a platform technology, biotechnology is the basis for companies with a wide range of different business models. We are looking positively to the future. If the right conditions are in place in Germany and Europe, the biotechnology industry will continue to establish itself as an important key industry in Germany.”
The range of business models is demonstrated by the presence of Laura Gertenbach (Managing Director Innocent Meat GmbH), Norbert Hentschel (Board Member and Treasurer BIO Deutschland, CFO Miltenyi Biotec), Oliver Schacht, PhD Chairman of the Board of BIO Deutschland, Managing Director/Life Science Nord Management GmbH), Roland Sackers (Board Member BIO Deutschland, CFO QIAGEN) and Dr. Claudia Ulbrich (CEO Cardior Pharmaceuticals, a subsidiary of Novo Nordisk) will be present at today's press event.
About BIO Deutschland:
BIO Deutschland e. V. is an independent biotechnology organization. The business association represents the interests of its members at national, European and global level. Biotechnology transfers biology into industrial application. It has already demonstrated visible benefits in medicine, for example. Innovative bio-based economic systems can enable Germany and Europe to achieve long-term sovereignty and prosperity. The network in the association is interdisciplinary and unique. The members conduct research, development, production and marketing globally. BIO Deutschland is a strong community. It relies on diversity, openness and equal opportunities and is committed to the free democratic basic order. Oliver Schacht, Ph. D., is chairman of the board of BIO Deutschland.
Further information is available at: www.biodeutschland.org
BIO Deutschland's supporting members and industry partners are:
AGC Biologics, Avia, Baker Tilly, Bayer, BioSpring, Boehringer Ingelheim, BüchnerBarella, Centogene, Citeline, CMS Hasche Sigle, Deutsche Bank, Ernst & Young, Evotec, KPMG, Lonza, Miltenyi Bi otec, MorphoSys, Novartis, Pfizer, PricewaterhouseCoopers, QIAGEN, Rentschler Biopharma, Roche Diagnostics, Sanofi Aventis Deutschland, Simmons & Simmons, Thermo Fisher Scientific, SpringerNature, Vertex Pharmaceuticals, Vibalogics, ZETA.
Contact:
BIO Deutschland e. V.
Dr. Claudia Englbrecht
Schützenstraße 6a
10117 Berlin
Tel.: +49 30 2332 164-32
Mobile: +49 151 14067326
E-Mail: englbrecht@biodeutschland.org